Cytokeratin 14/17 Rabbit Polyclonal Antibody

Order Now: brent@sdlifesciences.com

Anti-Cytokeratin 14/17 antibody
STJ98650 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cytokeratin 14/17.

Cytokeratin 14 (Cytokeratin 14) Antibody
20-abx009056
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
20-abx121588
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232195-100ug 100 ug
EUR 577.2

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232196-100ug 100 ug
EUR 610.8

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232197-100ug 100 ug
EUR 661.2

Cytokeratin 17 Polyclonal Antibody
40822-100ul 100ul
EUR 302.4

Cytokeratin 17 Polyclonal Antibody
40822-50ul 50ul
EUR 224.4

Cytokeratin 17 Polyclonal Antibody
ABP51128-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430

Cytokeratin 17 Polyclonal Antibody
ABP51128-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430

Cytokeratin 17 Polyclonal Antibody
ABP51128-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430

Cytokeratin 17 Polyclonal Antibody
ES2127-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Cytokeratin 17 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Cytokeratin 17 Polyclonal Antibody
ES2127-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Cytokeratin 17 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Cytokeratin 14 Polyclonal Antibody
41582-100ul 100ul
EUR 302.4

Cytokeratin 14 Polyclonal Antibody
41582-50ul 50ul
EUR 224.4

Cytokeratin 14 Polyclonal Antibody
ABP55033-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ABP55033-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ABP55033-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ABP52904-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ABP52904-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ABP52904-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14

Cytokeratin 14 Polyclonal Antibody
ES3903-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

Cytokeratin 14 Polyclonal Antibody
ES3903-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

Cytokeratin 14 Polyclonal Antibody
ES6032-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

Cytokeratin 14 Polyclonal Antibody
ES6032-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

Cytokeratin 17 Rabbit mAb
A3769 20 μL
EUR 18

Cytokeratin 17 Rabbit mAb
A3769-100ul 100 ul
EUR 492

Cytokeratin 17 Rabbit mAb
A3769-200ul 200 ul
EUR 685.2

Cytokeratin 17 Rabbit mAb
A3769-20ul 20 ul
EUR 265.2

Cytokeratin 17 Rabbit mAb
A3769-50ul 50 ul
EUR 344.4

Cytokeratin 14 Rabbit mAb
A19039-100ul 100 ul
EUR 492

Cytokeratin 14 Rabbit mAb
A19039-200ul 200 ul
EUR 685.2

Cytokeratin 14 Rabbit mAb
A19039-20ul 20 ul
EUR 265.2

Cytokeratin 14 Rabbit mAb
A19039-50ul 50 ul
EUR 344.4

Cytokeratin 17 Polyclonal Conjugated Antibody
C40822 100ul
EUR 476.4

Cytokeratin 14/16 Polyclonal Antibody
ABP55034-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80

Cytokeratin 14/16 Polyclonal Antibody
ABP55034-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80

Cytokeratin 14/16 Polyclonal Antibody
ABP55034-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80

Cytokeratin 14 (KRT14) polyclonal antibody
ABP-PAB-11625 100 ug Ask for price

Cytokeratin 14 Polyclonal Conjugated Antibody
C41582 100ul
EUR 476.4

Cytokeratin 14/16 Polyclonal Antibody
ES6033-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Cytokeratin 14/16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Cytokeratin 14/16 Polyclonal Antibody
ES6033-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Cytokeratin 14/16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Anti-Cytokeratin 17 Rabbit Monoclonal Antibody
M02289-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal Cytokeratin 17 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat.

Anti-Cytokeratin 14 Rabbit Monoclonal Antibody
M01432-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal Cytokeratin 14 Antibody. Validated in IP, IF, WB and tested in Human.

Anti-Cytokeratin 14 Rabbit Monoclonal Antibody
M01432-2 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal Cytokeratin 14 Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

Cytokeratin 17 antibody
70R-49983 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 17 antibody

Cytokeratin 17 antibody
70R-3229 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17

Cytokeratin 17 Antibody
48633-100ul 100ul
EUR 399.6

Cytokeratin 17 Antibody
48633-50ul 50ul
EUR 286.8

Cytokeratin 17 antibody
10R-7971 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 17 antibody
10R-C160a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 17 Antibody
AF7851 200ul
EUR 540

Cytokeratin 17 Antibody
DF6898 200ul
EUR 420

Cytokeratin 17 Antibody
AF5480 200ul
EUR 420

Cytokeratin 17 Antibody
AF0190 200ul
EUR 420

Cytokeratin 17 Antibody
V2176-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2176-20UG 20 ug
EUR 219
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2176IHC-7ML 7 ml
EUR 499
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2176SAF-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2669-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2669-20UG 20 ug
EUR 219
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2669IHC-7ML 7 ml
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V2669SAF-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V7128-100UG 100 ug
EUR 499
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki]

Cytokeratin 17 Antibody
V7128-20UG 20 ug
EUR 219
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki]

Cytokeratin 17 Antibody
V7128IHC-7ML 7 ml
EUR 499
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki]

Cytokeratin 17 Antibody
V7128SAF-100UG 100 ug
EUR 499
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki]

Cytokeratin 17 Antibody
V8796-100UG 100ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V8796-20UG 20ug
EUR 219
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V8796SAF-100UG 100ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9059-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9059-20UG 20 ug
EUR 219
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9059IHC-7ML 7 ml
EUR 499
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9059SAF-100UG 100 ug
EUR 499
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9167-100UG 100ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9167-20UG 20ug
EUR 219
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 17 Antibody
V9167SAF-100UG 100ug
EUR 499
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Cytokeratin 14 antibody
70R-49981 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 14 antibody

Cytokeratin 14 Antibody
48956-100ul 100ul
EUR 399.6

Cytokeratin 14 Antibody
48956-50ul 50ul
EUR 286.8

Cytokeratin 14 antibody
20R-CP002 100 ul
EUR 676.8
Description: Guinea Pig polyclonal Cytokeratin 14 antibody

Cytokeratin 14 antibody
10R-7970 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 14 antibody
10R-C159a 100 ug
EUR 766.8
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 14 Antibody
AF5225 200ul
EUR 420

Cytokeratin 14 Antibody
AF5370 200ul
EUR 420

Cytokeratin 14 (KRT14) Rabbit mAb
A19039 20 μL
EUR 18

Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody (RM351)
A1849-50
EUR 385.2

Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody (RM328)
A1842-50
EUR 373.2

Polyclonal KRT14 / CK14 / Cytokeratin 14 Antibody
APR03031G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human KRT14 / CK14 / Cytokeratin 14 . This antibody is tested and proven to work in the following applications:

Human Cytokeratin-17 (CK-17) Antibody
32066-05111 150 ug
EUR 313.2

Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody, Clone#RM351
M02101-3 100uL
EUR 476.4
Description: Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody, Clone#RM351 tested in WB, IHC, reactive to Human

Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody, Clone#RM328
M01432-3 100uL
EUR 462
Description: Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody, Clone#RM328 tested in WB, IHC, reactive to Human (Mouse or Rat)

Cytokeratin 7+17 Antibody
abx139682-01mg 0.1 mg
EUR 427.2

Cytokeratin 17 (CK17) Antibody
20-abx134382
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 17 (CK17) Antibody
20-abx009054
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin-17 (CK17) Antibody
abx019067-100ug 100 ug
EUR 410.4

Cytokeratin-17 (CK17) Antibody
abx413464-02ml 0.2 ml
EUR 460.8

Cytokeratin 17 (CK17) Antibody
abx232201-100ug 100 ug
EUR 577.2

Cytokeratin 17 (CK17) Antibody
abx232202-100ug 100 ug
EUR 661.2

Cytokeratin 17-Specific Antibody
abx232203-100ug 100 ug
EUR 577.2

Cytokeratin 17(E3) Antibody
BNC040158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF405S conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC040158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF405S conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC050158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF405M conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC050158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF405M conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCAP0158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCAP0158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCB0158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), Biotin conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCB0158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), Biotin conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCP0158-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 17(E3), PerCP conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCR0158-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 17(E3), RPE conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC940158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF594 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC940158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF594 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCA0158-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 17(E3), APC conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC810158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF680R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC810158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF680R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNUB0158-100 100uL
EUR 250.8
Description: Primary antibody against Cytokeratin 17(E3), Concentration: 0.2mg/mL

Cytokeratin 17(E3) Antibody
BNUB0158-500 500uL
EUR 549.6
Description: Primary antibody against Cytokeratin 17(E3), Concentration: 0.2mg/mL

Cytokeratin 17(E3) Antibody
BNCH0158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNCH0158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC880158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF488A conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC880158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF488A conjugate, Concentration: 0.1mg/mL

Cytokeratin 17 Conjugated Antibody
C48633 100ul
EUR 476.4

Cytokeratin 17(E3) Antibody
BNC680158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF568 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC680158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF568 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC470158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF647 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC470158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF647 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC430158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF543 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC430158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF543 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC610158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF660R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC610158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF660R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC800158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF680 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC800158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF680 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC400158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF640R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC400158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF640R conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC550158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF555 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC550158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF555 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC700158-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 17(E3), CF770 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNC700158-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 17(E3), CF770 conjugate, Concentration: 0.1mg/mL

Cytokeratin 17(E3) Antibody
BNUM0158-50 50uL
EUR 474
Description: Primary antibody against Cytokeratin 17(E3), 1mg/mL

Anti-Cytokeratin 17 antibody
PAab02201 100 ug
EUR 426

Anti-Cytokeratin 17 antibody
PAab02202 100 ug
EUR 494.4

anti- Cytokeratin 17 antibody
FNab02201 100µg
EUR 606.3
Description: Antibody raised against Cytokeratin 17

anti- Cytokeratin 17 antibody
FNab02202 100µg
EUR 702
Description: Antibody raised against Cytokeratin 17

Anti-Cytokeratin 17 antibody
STJ92630 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cytokeratin 17.

Anti-Cytokeratin 17 antibody
STJ97983 100 µl
EUR 280.8
Description: Mouse monoclonal to Cytokeratin 17.

Anti-Cytokeratin 17 antibody
STJ16100350 1 mL
EUR 1756.8

Anti-Cytokeratin 17 antibody
STJ180141 0.1 ml
EUR 254.4

Cytokeratin 7/17 Antibody
V8298-100UG 100 ug
EUR 499
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation.

Cytokeratin 7/17 Antibody
V8298-20UG 20 ug
EUR 219
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation.

Cytokeratin 7/17 Antibody
V8298SAF-100UG 100 ug
EUR 499
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation.

Cytokeratin 14(LL002) Antibody
BNC040499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF405S conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC040499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF405S conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC050499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF405M conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC050499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF405M conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCAP0499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCAP0499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCB0499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), Biotin conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCB0499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), Biotin conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCP0499-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 14(LL002), PerCP conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCR0499-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 14(LL002), RPE conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC940499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF594 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC940499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF594 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCA0499-250 250uL
EUR 459.6
Description: Primary antibody against Cytokeratin 14(LL002), APC conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC810499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF680R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC810499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF680R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNUB0499-100 100uL
EUR 250.8
Description: Primary antibody against Cytokeratin 14(LL002), Concentration: 0.2mg/mL

Cytokeratin 14(LL002) Antibody
BNUB0499-500 500uL
EUR 549.6
Description: Primary antibody against Cytokeratin 14(LL002), Concentration: 0.2mg/mL

Cytokeratin 14(LL002) Antibody
BNCH0499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNCH0499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC880499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF488A conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC880499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF488A conjugate, Concentration: 0.1mg/mL

Cytokeratin 14 Conjugated Antibody
C48956 100ul
EUR 476.4

Cytokeratin 14(LL002) Antibody
BNC680499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF568 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC680499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF568 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC470499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF647 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC470499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF647 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC400499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF640R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC400499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF640R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC430499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF543 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC430499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF543 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC610499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF660R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC610499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF660R conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC800499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF680 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC800499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF680 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC550499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF555 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC550499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF555 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC700499-100 100uL
EUR 238.8
Description: Primary antibody against Cytokeratin 14(LL002), CF770 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNC700499-500 500uL
EUR 652.8
Description: Primary antibody against Cytokeratin 14(LL002), CF770 conjugate, Concentration: 0.1mg/mL

Cytokeratin 14(LL002) Antibody
BNUM0499-50 50uL
EUR 474
Description: Primary antibody against Cytokeratin 14(LL002), 1mg/mL